Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 1, 2012Appointment Completes Company's CEO Transition Plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman
In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX) today named Michael F....
-
Oct 31, 2012This Innovative Bioabsorbable Coating is the First to Complete Absorption Shortly after Drug Elution Ends at Three Months
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 24, 2012
Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS...
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the...
-
Oct 23, 2012Twelve-Month Data Presented at TCT 2012 Support Safety and Efficacy of Epic Stent in Iliac Stenting
Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and...
-
Oct 23, 2012Results Presented on Cost Effectiveness and Clinical Benefits for Older Patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System Feasibility Trial Results Reviewed
Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.16 for the third quarter ended...
-
Oct 10, 2012REPRISE II Study Results Expected to Support CE Mark and Other Regulatory Filings
Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™...
-
Oct 9, 2012Victory™ guidewires are designed to facilitate crossing of resistant lesions
Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing...